quinazolines has been researched along with calcein am in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhardt, G; Buschauer, A; Gartner, M; Giannis, A; Gross, D; Müller, C; Sarli, V | 1 |
| Bi, YA; Campbell, S; Davidson, R; Duignan, DB; Dunn, MC; Feng, B; Kostrubsky, VE; Mireles, R; Smith, AR; Wang, HF; Xu, JJ | 1 |
| Bénard, J; Bidart, JM; Farinotti, R; Forestier, F; Gil, S; Jovelet, C | 1 |
3 other study(ies) available for quinazolines and calcein am
| Article | Year |
|---|---|
Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Dose-Response Relationship, Drug; Flow Cytometry; Fluoresceins; Glioblastoma; Humans; Insecticides; Kinesins; Molecular Structure; Paclitaxel; Pyrimidines; Quinazolines; Rotenone; Spindle Apparatus; Tetrahydroisoquinolines; Thiones; Time Factors; Tubulin; Tubulin Modulators; Vinblastine | 2007 |
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Calcium; Carrier Proteins; Cells, Cultured; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Fluoresceins; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Membrane Potentials; Mitochondrial Membranes; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Quinazolines; Receptor, ErbB-2 | 2009 |
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluoresceins; Fluorescent Dyes; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rhodamine 123; Time Factors | 2012 |